Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Ventana Medical Systems, Inc., is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide. The company passionately pursues its mission to improve the lives of all patients afflicted with cancer. Ventana Medical Systems discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments right here in southern Arizona for 80 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety. Ventana is committed to accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient. Ventana enables this with its global leadership as the number one Pharma Industry Partner of Choice in the development and commercialization of companion diagnostics for cancer patients. Ventana Medical Systems is a member of the Roche Group that is drawing on powerful partnerships with world-class scientific institutions.

Lumigen, Inc. develops, manufactures and markets chemicals. It distributes chemiluminescent reagents for the clinical immunodiagnostics markets. The firm’s Life Diagnostics SPARCL Kits, Western Blotting, ELISA and Hydrogen Peroxide Detection. The company was founded by A. Paul Schaap in 1987 and is headquartered in Southfield, MI.

THP is an emerging biotechnology company focused on research in the field of human antibody technologies. THP has developed a unique transgenic mammalian platform to create human antibodies. The technology will enable the generation of both monoclonal and polyclonal antibody therapeutics with enhanced efficacy.

Genomic Vision is a biotechnology company that combines pioneering Molecular Combing, a proprietary single DNA molecule detection technology, with biomarker discovery to develop and commercialize novel genetic tests and research tools for life sciences. Genomic Vision’s products focus on DNA analysis and genetic testing in the fields of cancer, rare inherited disorders and pharmacogenomics.

Quest Diagnostics Investments LLC, a subsidiary of Quest Diagnostics, Inc., is an American company specializing in medical laboratories.

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Shanghai Junshi Biosciences Co., Ltd. engages in the discovery, development, clinical research, and commercialization of biopharmaceutical drugs. Its products include toripalimab injection, UBP1211, JS002, and UBP1213. The company was founded by Zhuo Bing Zhang and Ji Kuan Shan on December 27, 2012 and is headquartered in Shanghai, China.

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Dako Denmark A/S designs and manufactures cancer diagnostic systems. It produces reagents, antibodies, instruments, and software solutions to make diagnoses and determine treatments for patients suffering from cancer. The firm's product areas encompass Immunohistochemistry, pharmacoDiagnostics, molecular pathology, Hematoxylin and Eosin stain, special stains, flow Cytometry, and specific proteins. The company was founded by Niels Harboe in 1966 and is headquartered in Glostrup, Denmark.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Suzhou Kebei Biotechnology Co., Ltd., established on 2009-09-10, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Development of Human Gene Diagnosis and Therapy Technology;Human stem cell technology development and application;R&D and application of cell technology;Medical Research and Experimental Development;Health Consulting Services(Does not include medical services);Conference and Exhibition Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Chongqing Yuzhong District Westen Experimental Instrument Business Department (hereinafter referred to as "Westen Biology", "Westen Diagnostics" and "Westen Biomedical") focuses on the transformation, application and development of global biomedical cutting-edge technologies, and is based on the national biomedical research and development cooperation, project incubation and achievement transformation. Now it has developed into a company focusing on the transformation of biomedical technologies, the development and entrepreneurship of molecular diagnostic products A high-tech group company engaged in the development of new biological drugs. The headquarters is set up in Chongqing High tech Zone, and the management team and operation organization are set up in Shanghai and Beijing. The company has seven service platforms: cell biology research platform, molecular biology research platform, pathology research platform, immunology research platform, animal model research platform, protein and polypeptide research platform, sequencing and chip research platform, and has provided hundreds of domestic and foreign research and development institutions and pharmaceutical enterprises with professional biological research and development testing cooperation and scientific and technological achievements transformation project guidance. In addition, the company has four innovation research and development centers: CRISPR/Cas9 targeted gene modified drug development platform, nano targeted drug delivery innovation platform, high-throughput, high connotation screening platform, and molecular diagnosis development platform. In addition to carrying out the company's research and development projects, the company can also provide collaborative research and development services for pharmaceutical enterprises, research and development teams, and research and development enterprises. At the same time, the company has more than 50 invention patents and is committed to the development of diagnostic products, functional medical testing, third-party medical testing and the research and development of gene drugs.

GenPharm International, Inc. engages in the development and application of HuMAb-Mouse transgenic animal technology. Its technology is used in the creation of human monoclonal antibodies for therapeutic uses. The company was founded in 1989 and is based in San Jose, California. As of October 21, 1997, GenPharm International, Inc. was a subsidiary of Medarex, Inc. Later, it operates as a subsidiary of Bristol-Myers Squibb Company.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

ARCH Development Corp., part of The University of Chicago, is an American company that provides job training and housing development services. Duane Gautier is currently the CEO of the firm.